|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FGFR2 |
Gene summary for FGFR2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FGFR2 | Gene ID | 2263 |
| Gene name | fibroblast growth factor receptor 2 | |
| Gene Alias | BBDS | |
| Cytomap | 10q26.13 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P21802 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2263 | FGFR2 | CA_HPV_1 | Human | Cervix | CC | 8.51e-05 | -1.49e-01 | 0.0264 |
| 2263 | FGFR2 | CA_HPV_3 | Human | Cervix | CC | 1.97e-23 | 4.50e-01 | 0.0414 |
| 2263 | FGFR2 | CCI_1 | Human | Cervix | CC | 6.18e-03 | 6.82e-01 | 0.528 |
| 2263 | FGFR2 | CCI_2 | Human | Cervix | CC | 1.04e-03 | 6.95e-01 | 0.5249 |
| 2263 | FGFR2 | CCI_3 | Human | Cervix | CC | 2.01e-02 | 5.07e-01 | 0.516 |
| 2263 | FGFR2 | HTA11_1938_2000001011 | Human | Colorectum | AD | 2.06e-04 | 4.09e-01 | -0.0811 |
| 2263 | FGFR2 | HTA11_78_2000001011 | Human | Colorectum | AD | 2.15e-10 | 7.37e-01 | -0.1088 |
| 2263 | FGFR2 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.90e-02 | 5.56e-01 | -0.1526 |
| 2263 | FGFR2 | HTA11_866_2000001011 | Human | Colorectum | AD | 8.09e-11 | 5.73e-01 | -0.1001 |
| 2263 | FGFR2 | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.04e-03 | 4.46e-01 | -0.059 |
| 2263 | FGFR2 | HTA11_546_2000001011 | Human | Colorectum | AD | 6.24e-03 | 5.32e-01 | -0.0842 |
| 2263 | FGFR2 | A008-E-015 | Human | Colorectum | FAP | 1.76e-02 | 2.45e-01 | 0.0177 |
| 2263 | FGFR2 | CRC-1-8810 | Human | Colorectum | CRC | 2.86e-02 | -1.80e-01 | 0.6257 |
| 2263 | FGFR2 | AEH-subject1 | Human | Endometrium | AEH | 1.28e-05 | 3.41e-01 | -0.3059 |
| 2263 | FGFR2 | AEH-subject3 | Human | Endometrium | AEH | 2.22e-08 | 3.63e-01 | -0.2576 |
| 2263 | FGFR2 | AEH-subject5 | Human | Endometrium | AEH | 2.41e-14 | 5.35e-01 | -0.2953 |
| 2263 | FGFR2 | EEC-subject1 | Human | Endometrium | EEC | 2.50e-13 | 5.55e-01 | -0.2682 |
| 2263 | FGFR2 | EEC-subject2 | Human | Endometrium | EEC | 1.22e-25 | 6.67e-01 | -0.2607 |
| 2263 | FGFR2 | EEC-subject5 | Human | Endometrium | EEC | 1.43e-05 | 2.79e-01 | -0.249 |
| 2263 | FGFR2 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 4.88e-11 | 2.52e-01 | -0.1869 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00605378 | Oral cavity | OSCC | muscle tissue development | 185/7305 | 403/18723 | 2.60e-03 | 1.14e-02 | 185 |
| GO:00308505 | Oral cavity | OSCC | prostate gland development | 27/7305 | 45/18723 | 3.49e-03 | 1.47e-02 | 27 |
| GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
| GO:00603484 | Oral cavity | OSCC | bone development | 99/7305 | 205/18723 | 4.13e-03 | 1.68e-02 | 99 |
| GO:003087910 | Oral cavity | OSCC | mammary gland development | 69/7305 | 137/18723 | 4.43e-03 | 1.79e-02 | 69 |
| GO:00426927 | Oral cavity | OSCC | muscle cell differentiation | 175/7305 | 384/18723 | 4.79e-03 | 1.92e-02 | 175 |
| GO:00486614 | Oral cavity | OSCC | positive regulation of smooth muscle cell proliferation | 54/7305 | 104/18723 | 5.00e-03 | 1.96e-02 | 54 |
| GO:00604256 | Oral cavity | OSCC | lung morphogenesis | 29/7305 | 50/18723 | 5.01e-03 | 1.96e-02 | 29 |
| GO:00606699 | Oral cavity | OSCC | embryonic placenta morphogenesis | 17/7305 | 26/18723 | 5.83e-03 | 2.23e-02 | 17 |
| GO:00486596 | Oral cavity | OSCC | smooth muscle cell proliferation | 89/7305 | 184/18723 | 5.95e-03 | 2.27e-02 | 89 |
| GO:00147067 | Oral cavity | OSCC | striated muscle tissue development | 174/7305 | 384/18723 | 6.45e-03 | 2.40e-02 | 174 |
| GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
| GO:00434107 | Oral cavity | OSCC | positive regulation of MAPK cascade | 213/7305 | 480/18723 | 8.71e-03 | 3.16e-02 | 213 |
| GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
| GO:00486606 | Oral cavity | OSCC | regulation of smooth muscle cell proliferation | 86/7305 | 180/18723 | 1.00e-02 | 3.49e-02 | 86 |
| GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
| GO:0032526 | Oral cavity | OSCC | response to retinoic acid | 54/7305 | 107/18723 | 1.04e-02 | 3.54e-02 | 54 |
| GO:00330024 | Oral cavity | OSCC | muscle cell proliferation | 115/7305 | 248/18723 | 1.05e-02 | 3.58e-02 | 115 |
| GO:00456674 | Oral cavity | OSCC | regulation of osteoblast differentiation | 65/7305 | 132/18723 | 1.06e-02 | 3.60e-02 | 65 |
| GO:003090116 | Oral cavity | OSCC | midbrain development | 46/7305 | 90/18723 | 1.30e-02 | 4.33e-02 | 46 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
| hsa040142 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
| hsa040109 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa0523010 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
| hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
| hsa0401513 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
| hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
| hsa0401411 | Cervix | CC | Ras signaling pathway | 51/1267 | 236/8465 | 3.55e-03 | 1.34e-02 | 7.91e-03 | 51 |
| hsa0401012 | Cervix | CC | MAPK signaling pathway | 62/1267 | 302/8465 | 4.89e-03 | 1.67e-02 | 9.86e-03 | 62 |
| hsa0523013 | Cervix | CC | Central carbon metabolism in cancer | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
| hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
| hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
| hsa05215 | Colorectum | AD | Prostate cancer | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
| hsa01521 | Colorectum | AD | EGFR tyrosine kinase inhibitor resistance | 29/2092 | 79/8465 | 1.15e-02 | 4.24e-02 | 2.71e-02 | 29 |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | ADJ |
| FGF1 | FGFR2 | FGF1_FGFR2 | FGF | Cervix | CC |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Cervix | CC |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | CRC | ADJ |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | CRC | CRC |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | ADJ |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | AEH |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | Endometrium | EEC |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Endometrium | EEC |
| FGF1 | FGFR2 | FGF1_FGFR2 | FGF | HNSCC | OSCC |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | OSCC |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | OSCC |
| FGF18 | FGFR2 | FGF18_FGFR2 | FGF | HNSCC | OSCC |
| FGF2 | FGFR2 | FGF2_FGFR2 | FGF | HNSCC | Precancer |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | HNSCC | Precancer |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AAH |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | ADJ |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | AIS |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | IAC |
| FGF7 | FGFR2 | FGF7_FGFR2 | FGF | Lung | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FGFR2 | SNV | Missense_Mutation | rs779423644 | c.364G>A | p.Val122Met | p.V122M | P21802 | protein_coding | deleterious(0.01) | possibly_damaging(0.902) | TCGA-3C-AALJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| FGFR2 | SNV | Missense_Mutation | c.338N>C | p.Val113Ala | p.V113A | P21802 | protein_coding | tolerated(0.52) | benign(0.1) | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| FGFR2 | SNV | Missense_Mutation | c.1763N>G | p.Ser588Cys | p.S588C | P21802 | protein_coding | tolerated(0.31) | possibly_damaging(0.857) | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FGFR2 | SNV | Missense_Mutation | c.785N>C | p.Leu262Pro | p.L262P | P21802 | protein_coding | deleterious(0.01) | probably_damaging(0.937) | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FGFR2 | SNV | Missense_Mutation | novel | c.1904N>C | p.Val635Ala | p.V635A | P21802 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FGFR2 | SNV | Missense_Mutation | rs121913474 | c.1147T>C | p.Cys383Arg | p.C383R | P21802 | protein_coding | deleterious(0.02) | possibly_damaging(0.865) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FGFR2 | SNV | Missense_Mutation | c.1650T>G | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FGFR2 | SNV | Missense_Mutation | c.1099N>C | p.Glu367Gln | p.E367Q | P21802 | protein_coding | tolerated(0.19) | benign(0.156) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| FGFR2 | SNV | Missense_Mutation | rs121913476 | c.1650T>A | p.Asn550Lys | p.N550K | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide+tamoxifen | SD |
| FGFR2 | SNV | Missense_Mutation | c.1414G>T | p.Asp472Tyr | p.D472Y | P21802 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A14W-01 | Breast | breast invasive carcinoma | Male | >=65 | I/II | Chemotherapy | cytoxan | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | AZ6089 | 22869148 | ||
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | CVBT-141H | |||
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | BGJ398 | INFIGRATINIB | |
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | DOVITINIB | DOVITINIB | ||
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | 252827519 | ||
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | TRAFERMIN | TRAFERMIN | ||
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | NINTEDANIB | NINTEDANIB | |
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | Trametinib | TRAMETINIB | 27338794 | |
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | CHEMBL1852688 | INFIGRATINIB | |
| 2263 | FGFR2 | KINASE, DRUGGABLE GENOME, TYROSINE KINASE, CLINICALLY ACTIONABLE, CELL SURFACE | inhibitor | LENVATINIB | LENVATINIB |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |